文献速递生殖医学

mRNA SARS-CoV-2 疫苗是否经精液分析反映对男性生育力产生不利影响

Does mRNA SARS-CoV-2 vaccine detrimentally affect male fertility, as reflected by semen analysis?
PubMed 文献 · Reprod Biomed Online · 2021-10-04

该前瞻性队列研究在以色列一家大型三级中心于2021年2月至3月开展,分析75名有生育力男性接种第二剂辉瑞COVID-19疫苗后1至2个月的精液样本,并与WHO参考范围比较。结果精液参数大多在正常范围内,异常率低于WHO报告的有生育力男性5%的水平。作者认为结果不支持疫苗对精液参数有因果性不利影响,并建议推荐给希望生育的男性。

要点

  • 接种第二剂辉瑞COVID-19疫苗后平均37天,75名有生育力男性精液参数大多在WHO正常参考范围内。
  • 仅1名参与者(1.3%)精子浓度为12.5×10^6/ml,被WHO视为少精症。
  • 仅1名男性(1.3%)精子活力百分比降低,未见明显形态学异常。

核心结论

  • 接种COVID-19疫苗后精液参数大多在WHO设定的正常参考范围内,不反映COVID-19疫苗有因果性不利影响。
  • 作者认为结果强化了辉瑞SARS-CoV-2疫苗安全的观点,并应推荐给希望生育的男性。

研究设计与样本

  • 前瞻性队列研究,在以色列一家大型三级中心于2021年2月至3月开展。
  • 分析75名有生育力男性接种第二剂辉瑞COVID-19疫苗后1至2个月的精液样本。
  • 精液参数与WHO参考范围比较,主要结局为接种者中异常精液参数百分比,即少精症率、精子活力百分比降低率和异常精子形态率。

主要发现

  • 从第二剂接种到参与日期平均37天,多数受试者描述第一剂或第二剂后副作用为轻度或无。
  • 平均精子浓度为63.2±33.6×10^6/ml,仅1名参与者(1.3%)精子计数为12.5×10^6/ml,被WHO视为少精症。
  • 平均精子活力百分比为64.5±16.7%,仅1名男性(1.3%)显示活力降低。
  • 未观察到明显形态学异常。
  • 异常精液参数百分比低于WHO报告的有生育力男性5%的比率。

临床怎么用

  • 作者认为辉瑞SARS-CoV-2疫苗安全,并应推荐给希望生育的男性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does Pfizer's coronavirus disease 2019 (COVID-19) vaccination detrimentally affect semen analysis parameters? DESIGN: A prospective cohort study was conducted at a single large tertiary centre in Israel between February and March of 2021. Semen samples from 75 fertile men were analysed 1-2 months following their second dose of Pfizer's COVID-19 vaccine. The semen parameters were compared with the World Health Organization (WHO) reference ranges. The primary outcome was the percentage of abnormal semen parameters in those who were vaccinated, i.e. the rates of oligozoospermia, reduced percentage of motile spermatozoa and abnormal sperm morphology. RESULTS: The interval from the time of the second vaccination to the date of participation was on average 37 days, with most subjects describing either mild or no side effects after the first or second dose. The mean sperm concentration was 63.2 ± 33.6 × 106/ml, with only a single participant (1.3%) with a sperm count of 12.5 × 106/ml, considered by the WHO to be oligozoospermic. The mean sperm motility percentage was 64.5 ± 16.7%, with only a single man (1.3%) displaying reduced motility. No notable morphological abnormalities were observed. This constituted a lower percentage of abnormal semen parameters compared with the 5% rates reported in fertile men by the WHO. CONCLUSIONS: The semen parameters following COVID-19 vaccination were predominantly within the normal reference ranges as set by the WHO and do not reflect any causative detrimental effect from COVID-19 vaccination. The results strengthen the notion that the Pfizer's severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine is safe and should be recommended to men wishing to conceive.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Lifshitz D, Haas J, Lebovitz O, et al. Does mRNA SARS-CoV-2 vaccine detrimentally affect male fertility, as reflected by semen analysis? Reprod Biomed Online. 2021. PMID: 34815157. doi:10.1016/j.rbmo.2021.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。